Zobrazeno 1 - 10
of 654
pro vyhledávání: '"Ronald F Van Vollenhoven"'
Autor:
Ronald F van Vollenhoven, Danielle M Gerlag, Karen I Maijer, Sander W Tas, Niek de Vries, Paul P Tak, Robert B M Landewé, Lisa G M van Baarsen, Giulia Frazzei, Sophie H M Cramer
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives Early treatment of individuals at risk of developing rheumatoid arthritis (RA-risk) in the preclinical phase has the potential to positively impact both patients and society by preventing disease onset and improving patients’ quality of
Externí odkaz:
https://doaj.org/article/1523f082a9b24d84afb908de20f35ef4
Autor:
Ronald F van Vollenhoven, Roy Fleischmann, Stephen Hall, Yanna Song, Sebastian Meerwein, Alvin F Wells, Oishi Tanjinatus
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Objective To evaluate the long-term sustainability of response to the Janus kinase inhibitor upadacitinib among patients with rheumatoid arthritis and an inadequate response or intolerance to biological disease-modifying antirheumatic drugs (bDMARD-I
Externí odkaz:
https://doaj.org/article/586ca3e848a64b7e8e3e8f420081088c
Autor:
Agner R. Parra Sánchez, Ronald F. van Vollenhoven, Eric F. Morand, Ian N. Bruce, Rangi Kandane-Rathnayake, Gudrun Weiss, Raj Tummala, Hussein Al-Mossawi, Alessandro Sorrentino
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1059-1061 (2024)
Externí odkaz:
https://doaj.org/article/808b953d2a8f4ae5a7971d120b868f7e
Autor:
Joan T Merrill, Ronald F van Vollenhoven, Daniel J Wallace, Susan Manzi, Cynthia Aranow, Anca Askenase, Michelle A Petri, Jill Buyon, Rosalind Ramsey-Goldman, Ian N Bruce, Guillermo Ruiz-Irastorza, Ellen M Ginzler, Graciela S Alarcón, John G Hanly, Murray B Urowitz, Juanita Romero-Diaz, Caroline Gordon, Sang-Cheol Bae, Anisur Rahman, Mary Anne Dooley, Paul R Fortin, Meggan Mackay, Andreas Jönsen, Sam Lim, Murat Inanc, Diane L Kamen, Christine A Peschken, Søren Jacobsen, Jorge Sanchez-Guerrero, David Isenberg, Marvin J Fritzler, Ann E Clarke, Sasha Bernatsky, Kenneth C Kalunian, Eugene Krustev, May Y Choi, Katherine A Buhler, Ricky Chin
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss 1 (2024)
Background Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia and CN. We as
Externí odkaz:
https://doaj.org/article/9208cd215f174ca8b2697b5bb89d40f3
Autor:
Ronald F van Vollenhoven, Merete Lund Hetland, Till Uhlig, Espen A Haavardsholm, Dan Nordström, Mikkel Østergaard, Michael T Nurmohamed, Sizheng Steven Zhao, Alf Kastbom, Bjorn Gudbjornsson, Meliha Crnkic Kapetanovic, Gerður Gröndal, Yuan Zhang, Kim Hørslev-Petersen, Anna Rudin, Jon Lampa, Kristina Lend, Tuulikki Sokka-Isler, Annika Söderbergh, Milad Rizk, Cristina Maglio, Marte Schrumpf Heiberg, Violetta Dubovyk, Georgios K Vasileiadis, Tahzeeb Fatima
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (
Externí odkaz:
https://doaj.org/article/6b01938d1e354a908fc7fc126fb8f00b
Autor:
Agner R. Parra Sánchez, Ronald F. van Vollenhoven, Eric F. Morand, Ian N. Bruce, Rangi Kandane-Rathnayake, Gudrun Weiss, Raj Tummala, Hussein Al-Mossawi, Alessandro Sorrentino
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1459-1477 (2023)
Abstract Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinica
Externí odkaz:
https://doaj.org/article/e1fcf1e203f84ba88cc0a6c10e3a1017
Autor:
Joseph F Merola, Subhashis Banerjee, Eric Morand, Piotr Leszczyński, Marilyn Pike, Ronald F van Vollenhoven, Coburn Hobar, Kathryn H Dao, Samantha Pomponi, Matthew J Colombo, Ravi Koti, Thomas Wegman
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/27bdd3d6ad944e9a8be79d1d8827b64c
Autor:
Ronald F van Vollenhoven, Bente Glintborg, Merete Lund Hetland, Ulf Lindström, Brigitte Michelsen, Elsa Vieira-Sousa, Florenzo Iannone, Eirik Klami Kristianslund, Dan Nordström, Karel Pavelka, Ziga Rotar, Maria Jose Santos, Catalin Codreanu, Gary J Macfarlane, Mikkel Østergaard, Michael T Nurmohamed, Jiri Vencovsky, Rosario Foti, Bjorn Gudbjornsson, Matija Tomšič, Lykke Midtbøll Ørnbjerg, Adrian Ciurea, Árni Jón Geirsson, Irene van der Horst-Bruinsma, Michael S Nissen, Ovidiu Rotariu, Isabel Castrejón, Johan K Wallman, Marleen van de Sande, Anne G Loft, Pasoon Hellamand, Thomas Klausch, Anna Mari Hokkanen, Corina Mogosan, Lucia Otero-Varela, Semih Gulle, Berrin Zengin
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axS
Externí odkaz:
https://doaj.org/article/e6632f400b4e4c9eb966b1dc4cf15287
Autor:
Thomas Dörner, Ronald F. van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A. Ross Terres, Maria E. Silk, Stephanie de Bono, Peter Fischer, Daniel J. Wallace
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-9 (2022)
Abstract Background Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical tria
Externí odkaz:
https://doaj.org/article/4d118c8e78e2474c874245f67f839d0d
Autor:
Victoria P Werth, Ronald F van Vollenhoven, Kenneth Kalunian, Karen Costenbader, Eric F Morand, Peter Lipsky, Christopher Reed, Laura Eve Schanberg, Zahi Touma, Anca D Askanase, Lauren Bloch, Timothy Franson, L Inês, Joy Buie, MaryBeth Son
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss 1 (2023)
Drug development in lupus has improved over the past 10 years but still lags behind that of other rheumatic disease areas. Assessment of prospective lupus therapies in clinical trials has proved challenging for reasons that are multifactorial includi
Externí odkaz:
https://doaj.org/article/7f388926b5e646f787d5f1417c696325